DocWire News Editors

DocwireNews

When receiving treatment for Age-Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME), patients most value optimal vision outcomes and limited out-of-pocket costs, according to a study presented at the 37th ASRS Annual Meeting by Davis Bhagat, BS, MA, from University Retina in Oak Forest, IL.The researchers conducted small focus groups to discern which factors patients most valued when undergoing AMD or DME treatment. After establishing the desired variables, they surveyed 300 patients across three retina clinics using a prospective, consecutive series approach on established patients with AMD or DME who received laser or intravitreal therapy. Demographic data based on age, gender, and education level showed that 1.3% of participants were between the ages of 18-39, 21% were between the ages of 40 and 64, 44% were between the ages of 65 and 79, and 34% were 80 plus. Moreover, 54% of participants were female, 67% had only completed high school, 8% failed to complete high school, and 19% and 5% had received an undergraduate or graduate degree, respectively.&nbsp; The study measures comprised the importance of treatment cost, efficacy in the context of vision gain, durability of treatment, and drug label status. The researchers analyzed the data using survey analytics software.Upon data analysis, the findings showed that the most important treatment attribute for patients was treatment that led to good vision, demonstrating 40.4% relative importance.&nbsp; The second most important attribute (23% relative importance) was a low cost of medication to the patient.&nbsp; The third most important attribute was on-label status with a 21% relative importance.&nbsp; The frequency of visits was less important demonstrating 12.2% relative importance, and the least important factor was the cost of treatment to the insurance provider with only a 3% relative importance.&ldquo;The most important treatment attribute appears to be superior vision outcomes with out-of-pocket costs a higher concern than cost to the system,&rdquo; the study authors noted, adding that as &ldquo;patient-centered care continues to grow and financial burdens shift from system to patient, this analysis highlights patient preferences that should be considered in creating individual treatment plans.&rdquo;Bhagat D. Evaluating Patient Preferences When Receiving Intravitreal Injections or Laser for Retinal Disease: A Conjoint Analysis. Presented at the 37th ASRS Annual Meeting; July 26-30, 2019; Chicago, IL.Read more (login required): <a href="https://meeting2019.asrs.org/posters#/posters/evaluating-patient-preferences-when-receiving-intravitreal-injections-or-la-263">https://meeting2019.asrs.org/posters#/posters/evaluating-patient-preferences-when-receiving-intravitreal-injections-or-la-263</a>

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Evaluating Patient Preferences When Receiving Intravitreal Injections or Laser for Retinal Disease: A Conjoint Analysis

ASRS 2019

When receiving treatment for Age-Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME), patients most value optimal vision outcomes and limited out-of-pocket ...

Evaluating Patient Preferences When Receiving Intravitreal Injections or Laser for Retinal Disease:

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe